Cyclic tetrameric compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders

摘要

The present invention provides an inhibitor of PCSK9 useful in the treatment of cholesterol lipid metabolism and other diseases in which PCSK9 plays a predetermined role, wherein an inhibitor of PCSK9 having the following formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof , a stereoisomer, an N-oxide, or a tautomer: [Formula I] wherein R ₁ , R ₁ , R ₁ , R ₁ , R ₁ , R ₁ , R ₁ , R ₁ , R ₁ , X ₁ , X ₂ , and X ₃ are described herein.